<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01773174</url>
  </required_header>
  <id_info>
    <org_study_id>1160.145</org_study_id>
    <nct_id>NCT01773174</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to &lt; 2 Years of Age</brief_title>
  <official_title>Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Children Aged 1 Year to Less Than 2 Years in Conjunction With Study 1160.89</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study will assess PK/PD parameters and safety and tolerability of the study medication in
      this age group
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ecarin clotting time (ECT)</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Factor IIa inhibition</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of all bleeding events</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of all adverse events</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of total dabigatran</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of free dabigatran</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of BIBR 1048 BS (Base)</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of BIBR 951 BS</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentrations of BIBR 1087 SE (Acid)</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Activated prothrombin time (aPTT)</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global assessment of tolerability will be summarized across all patients in the treated set</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient assessment of taste will be summarized across all patients in the treated set</measure>
    <time_frame>one day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in laboratory and clinical parameters</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>dabigatran etexilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose treatment with dabigatran oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran etexilate</intervention_name>
    <description>age &amp; weight adjusted equivalent of adult dose</description>
    <arm_group_label>dabigatran etexilate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. males or females 1 to less than 2 years of age

          2. objective diagnosis of primary venous thromboembolism

          3. completion of planned treatment course with low molecular weight heparin or oral
             anticoagulant for primary venous thromboembolism

          4. written informed consent by parent (legal guardian) and patient assent (if applicable)

        Exclusion criteria:

          1. weight less than 9 kg

          2. conditions associated with increased risk of bleeding

          3. patients who have any condition that would not allow safe participation in study Note:
             Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.145.00010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.145.00009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.145.00008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.145.00012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.145.00007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.145.0006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.145.00001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.145.00011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2013</study_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

